Key Information
Recent transthyretin cardiac amyloidosis (ATTR-CM) trial data suggest that outcomes for some treated patients may now be approaching age-expected survival, marking a major shift in how clinicians think about transthyretin cardiac amyloidosis. This article centers around HELIOS-B, the randomized trial showing that vutrisiran significantly reduced all-cause death and recurrent cardiovascular events, lowered hospitalizations, and helped preserve functional capacity and quality of life. It also highlights a widely discussed figure comparing survival curves across major ATTR-CM trials with actuarial survival in the general population. Experts say this suggests the field is moving toward a point where many patients may live with cardiac amyloidosis rather than die from it, especially when treatment is started early.
The article also reviews a HELIOS-B echocardiographic sub study. It found that worse baseline left and right ventricular function predicted poorer outcomes. It further showed that vutrisiran improved or slowed worsening in several measures of cardiac structure and function over time, including diastolic function and declines in systolic performance. These imaging findings are presented as a possible explanation for the broader clinical benefits seen in the trial and as a step toward better monitoring of treatment response. The larger message is that optimal outcomes in ATTR-CM still depend on earlier recognition and an appropriate diagnostic workup, including nuclear scintigraphy as a first-line strategy. They also depend on starting disease-modifying therapy before more advanced cardiac damage develops.